Literature DB >> 12064376

Pharmacokinetics of phenytoin following intravenous and intramuscular administration of fosphenytoin and phenytoin sodium in the rabbit.

S N Muchohi1, G O Kokwaro, T E Maitho, R W Munenge, W M Watkins, G Edwards.   

Abstract

The purpose of this study was to evaluate and compare plasma phenytoin concentration versus time profiles following intravenous (i.v.) and intramuscular (i.m.) administration of fosphenytoin sodium with those obtained following administration of standard phenytoin sodium injection in the rabbit. Twenty-four adult New Zealand White rabbits (2.1 +/- 0.4 kg) were anaesthetized with sodium pentobarbitone (30 mg/kg) followed by i.v. or i.m. administration of a single 10 mg/kg phenytoin sodium or fosphenytoin sodium equivalents. Blood samples (1.5 ml) were obtained from a femoral artery cannula predose and at 1, 3, 5, 7, 10, 15, 20, 30, 45, 60, 90, 120, 180, 240 and 300 min after drug administration. Plasma was separated by centrifugation (1000 g; 5 min) and fosphenytoin, total and free plasma phenytoin concentrations were measured using high performance liquid chromatography (HPLC). Following i.v. administration of fosphenytoin sodium plasma phenytoin concentrations were similar to those obtained following i.v. administration of an equivalent dose of phenytoin sodium. Mean peak plasma phenytoin concentrations (Cmax) was 158% higher (P = 0.0277) following i.m. administration of fosphenytoin sodium compared to i.m. administration of phenytoin sodium. The mean area under the plasma total and free phenytoin concentration-time curve from time zero to 120 min (AUC(0-120)) following i.m. administration was also significantly higher (P = 0.0277) in fosphenytoin treated rabbits compared to the phenytoin group. However, there was no significant difference in AUC(0-180) between fosphenytoin and phenytoin-treated rabbits following i.v. administration. There was also no significant difference in the mean times to achieve peak plasma phenytoin concentrations (Tmax) between fosphenytoin and phenytoin-treated rabbits following i.m. administration. Mean plasma albumin concentrations were comparable in both groups of animals. Fosphenytoin was rapidly converted to phenytoin both after i.v. and i.m. administration, with plasma fosphenytoin concentrations declining rapidly to undetectable levels within 10 min following administration via either route. These results confirm the rapid and complete hydrolysis of fosphenytoin to phenytoin in vivo, and the potential of the i.m. route for administration of fosphenytoin delivering phenytoin in clinical settings where i.v. administration may not be feasible.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12064376     DOI: 10.1007/BF03190421

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  23 in total

1.  Effect of phenobarbital on seizure frequency and mortality in childhood cerebral malaria: a randomised, controlled intervention study.

Authors:  J Crawley; C Waruiru; S Mithwani; I Mwangi; W Watkins; D Ouma; P Winstanley; T Peto; K Marsh
Journal:  Lancet       Date:  2000-02-26       Impact factor: 79.321

Review 2.  Fosphenytoin (Cerebyx).

Authors:  T R Browne
Journal:  Clin Neuropharmacol       Date:  1997-02       Impact factor: 1.592

3.  Pharmacokinetics and safety of a phenytoin prodrug given i.v. or i.m. in patients.

Authors:  I E Leppik; B A Boucher; B J Wilder; V S Murthy; C Watridge; N M Graves; R J Rangel; C A Rask; P Turlapaty
Journal:  Neurology       Date:  1990-03       Impact factor: 9.910

4.  Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653) administration to humans.

Authors:  B D Jamerson; K H Donn; G E Dukes; J A Messenheimer; K L Brouwer; J R Powell
Journal:  Epilepsia       Date:  1990 Sep-Oct       Impact factor: 5.864

5.  Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa.

Authors:  B M Greenwood; A K Bradley; A M Greenwood; P Byass; K Jammeh; K Marsh; S Tulloch; F S Oldfield; R Hayes
Journal:  Trans R Soc Trop Med Hyg       Date:  1987       Impact factor: 2.184

Review 6.  Intramuscular use of fosphenytoin: an overview.

Authors:  B M Uthman; B J Wilder; R E Ramsay
Journal:  Neurology       Date:  1996-06       Impact factor: 9.910

7.  Phenytoin pharmacokinetics in the rabbit: evidence of rapid autoinduction.

Authors:  B J Cusack; D A Tesnohlidek; V L Loseke; R M Eggerth; R D Olson
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1987-11

8.  Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration.

Authors:  B A Boucher; A M Bombassaro; S N Rasmussen; C B Watridge; R Achari; P Turlapaty
Journal:  J Pharm Sci       Date:  1989-11       Impact factor: 3.534

9.  Clinical features and prognostic indicators in paediatric cerebral malaria: a study of 131 comatose Malawian children.

Authors:  M E Molyneux; T E Taylor; J J Wirima; A Borgstein
Journal:  Q J Med       Date:  1989-05

Review 10.  Neurological sequelae of cerebral malaria in children.

Authors:  D R Brewster; D Kwiatkowski; N J White
Journal:  Lancet       Date:  1990-10-27       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.